中肽生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
PARP-014A
PAR-4 (1-6) amide (mouse)
H-Gly-Tyr-Pro-Gly-Lys-Phe-NH2 Trifluoroacetate salt
H-Gly-Tyr-Pro-Gly-Lys-Phe-NH2 Trifluoroacetate salt
Size：5mg
P1(RMB)：314
MW：666.78
One letter sequence：GYPGKF-NH2
Molecular Formula：C33H46N8O7
Description：Protease-activated receptor-4 activating peptide derived from murine PAR-4. This peptide was able to cause rat platelet aggregation with an EC50 value of 40 µM. Its effect on leucocyte rolling and adherence points at a role of PAR-4 in mediating proinflammatory processes. The family of at least seven transmembrane G protein coupled receptors includes at least four receptor subtypes (PAR1, PAR2, PAR3, PAR4). PAR4 activating peptides, GYPGKF-NH2 and AYPGKG-NH2, produce concentration dependent contractile effects on the muscle.
Literature Reference：N.Vergnolle, J. Immunol., 163, 5064 (1999) M.D.Hollenberg and M.Saifeddine, Can. J. Physiol. Pharmacol., 79, 439 (2001) Ref: Fang, J. et al. Blood 106, 2671(2005) Mulè, F. et al. Gut. 53, 229 (2004) Sekiguchi, F. et al. Drug Design Rev. 1, 287 (2004) Faruqi, T. et al. J. Biol. Chem. 275, 19728 (2000) Greenberg, D. Biochem. 42, 2702 (2003) Henriksen, R. and V. Hanks, Arterioscler. Thromb. Vasc. Biol. 22, 861 (2002) Gui, Y. et al. Am. J. Physiol. Renal. Physiol. 285, 95 (2003).
Cas：245443-52-1
P1(RMB)：314
MW：666.78
One letter sequence：GYPGKF-NH2
Molecular Formula：C33H46N8O7
Description：Protease-activated receptor-4 activating peptide derived from murine PAR-4. This peptide was able to cause rat platelet aggregation with an EC50 value of 40 µM. Its effect on leucocyte rolling and adherence points at a role of PAR-4 in mediating proinflammatory processes. The family of at least seven transmembrane G protein coupled receptors includes at least four receptor subtypes (PAR1, PAR2, PAR3, PAR4). PAR4 activating peptides, GYPGKF-NH2 and AYPGKG-NH2, produce concentration dependent contractile effects on the muscle.
Literature Reference：N.Vergnolle, J. Immunol., 163, 5064 (1999) M.D.Hollenberg and M.Saifeddine, Can. J. Physiol. Pharmacol., 79, 439 (2001) Ref: Fang, J. et al. Blood 106, 2671(2005) Mulè, F. et al. Gut. 53, 229 (2004) Sekiguchi, F. et al. Drug Design Rev. 1, 287 (2004) Faruqi, T. et al. J. Biol. Chem. 275, 19728 (2000) Greenberg, D. Biochem. 42, 2702 (2003) Henriksen, R. and V. Hanks, Arterioscler. Thromb. Vasc. Biol. 22, 861 (2002) Gui, Y. et al. Am. J. Physiol. Renal. Physiol. 285, 95 (2003).
Cas：245443-52-1
